ADC Therapeutics S.A. (ADCT) Stock Score, Valuation & Financial Research
ADC Therapeutics S.A. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 15/100.
Quick answer for ADCT
ADC Therapeutics S.A. currently has a Wall Street Score of 15/100. The stored market price is $1.11. Its financial score is 12/100. Its valuation score is 0/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What ADC Therapeutics S.A. does
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furt
ADCT financial snapshot
- Wall Street Score:
- 15/100
- Current price:
- $1.11
- Market capitalization:
- $141.2M
- Revenue:
- $78.8M
- Net income:
- $-96.9M
- Free cash flow:
- $-141.4M
- Cash:
- $219.1M
- Total debt:
- $417.1M
- EPS:
- -0.66
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 11/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $-141.4M, showing cash burn in the current stored period.
- The balance sheet shows $219.1M of cash versus $417.1M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.1 points: ADCT increased 0.1 points because overall fundamentals improved.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ADCT
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.